

NEWS RELEASE

9 October 2024

DR CHRIS BURNS ANNOUNCED AS CO-RECIPIENT OF 2024 PRIME MINISTER'S PRIZE FOR INNOVATION

HIGHLIGHTS

- Amplia CEO and MD, Dr Chris Burns, together with long-time scientific collaborator, Prof. Andrew Wilks, have received the coveted 2024 Prime Minister's Prize for Innovation.
- The scientists are recognised for their outstanding contribution to drug discovery and development in Australia, with their invention of momelotinib to treat myelofibrosis.

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), ("Amplia" or the "Company"), is pleased to announce Amplia CEO and MD, Dr Chris Burns, together with Professor Andrew Wilks are co-recipients of the Prime Minister's Prize for Innovation. They received the award at a Gala Dinner celebrating the Prime Minister's Prizes for Science at Parliament House in Canberra last night.

Dr Burns and Professor Wilks received the Prime Minister's Prize for Innovation in recognition of their outstanding contribution to drug discovery and development in Australia, with Wilks' discovery of the JAK enzymes and their co-invention of the JAK inhibitor momelotinib, a drug to help treat a rare form of bone marrow cancer called myelofibrosis. The drug was discovered when the pair worked at Melbourne-based biotechnology company Cytopia.

Momelotinib was approved by the US Food and Drug Administration (FDA) in 2023 – making history as one of only two Australian-invented drugs to attract approval from the world's peak health regulatory body.

Momelotinib was acquired by one of the world's leading pharmaceutical companies for US\$1.9 billion (AU\$2.92 billion). It is currently marketed in the USA under the brand name Ojjaara.

Amplia CEO and MD, Dr Chris Burns, commented: "I am extremely honoured to be the co-recipient of the 2024 Prime Minister's Prize for Innovation. Australia does a lot of fantastic early-stage research. What we've done in the discovery and development of momelotinib shows that incredible research can be translated here in Australia."

This announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx), [Threads](https://www.threads.net/@ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/amplia-therapeutics).